Evidence map›Paper›PMID 40702143›Full record

ArticleScientific reports2025

Comparative analysis of cutaneous features of psoriasis in acute and chronic imiquimod-induced mouse models.

Emma Fraillon, Jean-François Jégou, Hanitriniaina Rabeony, Jean-Claude Lecron, Nicolas Lebonvallet, Emilie Marie-Joseph, Audrey Josset-Lamaugarny, Géraldine Aimond, Laurent Misery, Franck Morel and 2 more

Erratum issuedAbstract readComparative Study
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Emma FraillonLaboratoire de Biologie Tissulaire et Ingénierie Thérapeutique, CNRS UMR5305, Université Claude Bernard Lyon 1, Lyon, France.
Jean-François JégouLaboratoire Inflammation, Tissus Épithéliaux et Cytokines, Université de Poitiers UR15560, Poitiers, France.
Hanitriniaina RabeonyLaboratoire Inflammation, Tissus Épithéliaux et Cytokines, Université de Poitiers UR15560, Poitiers, France.
Jean-Claude LecronLaboratoire Inflammation, Tissus Épithéliaux et Cytokines, Université de Poitiers UR15560, Poitiers, France.
Nicolas LebonvalletLaboratoire Interactions Épithéliums Neurones, Univ Brest UR4685, Brest, France.
Emilie Marie-JosephLaboratoire Interactions Épithéliums Neurones, Univ Brest UR4685, Brest, France.
Audrey Josset-LamaugarnyLaboratoire de Biologie Tissulaire et Ingénierie Thérapeutique, CNRS UMR5305, Université Claude Bernard Lyon 1, Lyon, France.
Géraldine AimondLaboratoire de Biologie Tissulaire et Ingénierie Thérapeutique, CNRS UMR5305, Université Claude Bernard Lyon 1, Lyon, France.
Laurent MiseryLaboratoire Interactions Épithéliums Neurones, Univ Brest UR4685, Brest, France.
Franck MorelLaboratoire Inflammation, Tissus Épithéliaux et Cytokines, Université de Poitiers UR15560, Poitiers, France.
Fabien P ChevalierLaboratoire de Biologie Tissulaire et Ingénierie Thérapeutique, CNRS UMR5305, Université Claude Bernard Lyon 1, Lyon, France.
Bérengère FromyLaboratoire de Biologie Tissulaire et Ingénierie Thérapeutique, CNRS UMR5305, Université Claude Bernard Lyon 1, Lyon, France. berengere.fromy@cnrs.fr.

Funding

Agence Nationale de la Recherche ANR-19-CE14-0006
6 · The paper itself

Abstract

Psoriasis is a chronic inflammatory skin disorder influenced by genetic and environmental factors. The imiquimod (IMQ)-induced mouse model is widely used to study psoriasis-like skin inflammation. However, its current use is largely limited to short treatment periods. Therefore, this model predominantly reflects acute inflammation and is limited in its capacity to capture the chronic nature of psoriasis. To date, little attention has been given to the extension of IMQ treatment duration to study the characteristics of sustained inflammation. This study aimed to provide the first direct comparison between short-term (ST, 4 days) and long-term (LT, 9 weeks) IMQ treatments on cutaneous histological, molecular and functional psoriasis features and to assess their similarity with human psoriasis. Both models demonstrated similar global severity, but with distinct features: ST-IMQ treatment led to increased epidermal hyperplasia and impaired skin barrier function, while LT-IMQ treatment was associated with greater desquamation and impaired suprabasal differentiation. Dermal mechanical properties and endothelial dysfunction were similar between the two models. Gene expression analysis revealed differentially expressed psoriasis-related markers between ST- and LT-IMQ treatments, with both models showing similarities to human psoriasis. These findings offer critical insights into how acute and chronic models can be tailored to study specific psoriasis features.

Indexed as

ImiquimodPsoriasisSkinAcute DiseaseAnimalsChronic DiseaseDisease Models, AnimalFemaleHumansMiceImiquimod

Identifiers

PMID40702143
PMCPMC12287311

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.